This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Novel UBE2B-associated polymorphisms in an
azoospermic/oligozoospermic population
Ivan Huang1, Benjamin R.
Emery2, Greg L. Christensen2, Jeanine
Griffin2, C. Matthew
Peterson1, Douglas T. Carrell2
1Division of Reproductive Endocrinology,
2Andrology and IVF Laboratories, University of Utah Health Sciences, Salt Lake
City, Utah 84106, USA
Abstract
Aim: To assess whether abnormalities exist in the
UBE2B gene in a population of infertile human males, and to
establish biologic plausibility of any discovered mutations.
Methods: We carried out polymerase chain reaction (PCR)
amplification and sequence analysis of the 5'-untranslated region and six exons of the
UBE2B gene, including flanking intronic regions, in a group of fertile and infertile men. Following the identification of a putative promoter region that
contained single or dual triplet deletions within a 10-CGG repeat island, we evaluated the binding affinity of these
identified polymorphisms as compared to the wild-type sequence to transcription factor SP1 using a DNA_protein gel
shift assay. Results: There was a novel exonic
single nucleotide polymorphism (SNP) noted in exon 4 in 5% of
infertile men. In silico 3D modeling of the altered protein showed an innocuous isoleucine for valine substitution.
There were no mutations noted within any of the other exons. Three novel intronic SNPs were identified within the
fertile group, and seven novel intronic SNPs identified in the infertile group. The DNA_protein gel shift assay noted
that both single CGG deletion and double CGG deletion bands had approximately twice the binding affinity compared
to the wild-type for SP1. The negative control confirmed no non-specific protein binding.
Conclusion: By themselves, a single or double CGG deletion is unlikely to pose biologic significance. However, such deletions in this suspected
promoter region are associated with increased binding affinity for SP1, and might represent one of several factors
required for alteration of UBE2B gene expression.
(Asian J Androl 2008 May; 10: 461_466)
Keywords: UBE2B; SP1; spermatogenesis; male infertility; single nucleotide polymorphism
Correspondence to: Dr Ivan Huang, 30 North Medical Drive, University of Utah Health Sciences, Salt Lake City, Utah 84106, USA.
Tel: +1-801-581-3834 Fax +1-801-585-2388
E-mail: fertilitydr@hsc.utah.edu
Received 2007-10-18 Accepted 2007-12-16
DOI: 10.1111/j.1745-7262.2008.00386.x
1 Introduction
UBE2A and UBE2B are mammalian homologs of
RAD6 in yeast, and have 96% and 100% amino acid
(a.a.) identity to RAD6, respectively.
UBE2B encodes a key protein in a pathway essential for post-replicative DNA repair
(RAD6 pathway) and has been shown in the mouse knockout to lead to infertile male mice [1]. This infertility has
been shown to occur through disruption of primary prophase and to increase apoptosis of primary spermatocytes [2].
Of interest, the UBE2A male mouse knockout is fertile but the
UBE2A female is not. UBE2A null oocytes fertilized
with wild-type (WT) sperm fail to pass the two-cell block [3].
The UBE2B gene is located on the long arm of chromosome 5 (5q31.1), has six exons spanning a length of
approximately 21 000 bp, and encodes a protein of approximately 150 a.a. It is one of a number of candidate genes
for male infertility and thought to be critically involved with spermatogenesis [1]. It is commonly referred to as
HR6B or the RAD6 yeast homolog. In humans, there are
currently 147 known polymorphisms of the
UBE2B gene [4], none of which have been reported to be associated
with male infertility.
Our goal for this study was to evaluate the
candidacy of the UBE2B gene as a factor in human male
infertility. We planned to sequence the
UBE2B gene and its promoter region in a group of infertile human males
with severe oligozoospermia or non-obstructive
azoospermia, and, following comparison of any identified
mutations to a reference population of fertile men, carry out
appropriate studies to establish biologic plausibility.
2 Materials and methods
In the population of infertile males attending the Utah
Center for Reproductive Medicine (Salt Lake City, UT,
USA), 96 men with severe oligozoospermia (less than
5 × 106/mL) or non-obstructive azoospermia were
identified. Men were identified as azoospermic if the
ejaculate was confirmed to be void of any sperm by
centrifugation of the ejaculate and evaluation of the seminal
pellet by at least two trained technicians. The diagnosis
of severe oligozoospermia or azoospermia was conducted
in a College of American Pathologists certified andrology
clinic following American Society of Reproductive
Medicine guidelines. Individuals diagnosed with any
condition or treatment connected with infertility (obstructive
azoospermia, cystic fibrosis, varicocele, or prior
exposure to chemotheraputics) were excluded. Genomic DNA
was prepared from peripheral blood and stored until
analysis was ready to be carried out.
Genomic DNA of 96 men with proven fertility was
obtained from the Utah Genetic Reference Project (UGRP)
and served as fertile controls. To ensure paternity of the
fertile controls from the UGRP, men were chosen from
generations of the UGRP where there are records of,
and genetic verification of, a subsequent generation. Men
from both study and control groups were of northern
European descent.
2.1 Polymerase chain reaction (PCR) analysis of
5'-untranslated region (UTR) and exons
Promoter identification software was used to
identify a putative promoter region in the 5'-UTR of the
UBE2B gene [5, 6]. PCR primers (Table 1) were
developed and optimized to amplify the region 500 bp upstream
of the UBE2B coding region encompassing this putative
promoter region. Six sets of PCR primers were also
developed and optimized to amplify the six exons of
UBE2B with a range of 70_200 bp flanking the upstream
and downstream sequences of the exons. Unless
specified, forward or reverse amplification primers were also
used as sequencing primers, otherwise internal
sequencing primers were used for sequencing.
Sequencing was conducted on an ABI 3700 capillary
sequencer (Applied Biosystems; Foster City, CA, USA).
Sequence trace files generated by the ABI 3700 were
assembled using Phrap program software (www.phrap.org) and evaluated for alterations using both Phred and
Consed sequence analysis programs (www.phrap.org).
2.2 In silico protein analysis of exonic single nucleotide
polymorphism (SNP)
The altered UBE2B a.a. sequence was generated from
exonic SNP data in-frame with the WT UBE2B a.a.
sequence. In silico models of tertiary protein structures
were then created using Swiss-Model [7] using these
linear a.a. sequences as templates. Next, comparison of
tertiary protein structures was carried out using the
Local_Global Alignment method of protein structure
analysis [8].
2.3 Analysis of DNA_protein binding affinity
An in silico model [9] was used to identify several
transcription factors applicable to the region of interest,
and narrowed to transcription factor SP1 given its prior
description in published reports as being active in
spermatogenesis [10, 11]. Recombinant SP1 was purchased
from Promega (Madison, WI, USA).
Three oligonucleotides representing the most
common length CGG repeat and two polymorphic variants
identified in gene sequencing were purchased through
the Oligonucleotide/Peptide Synthesis facility located at
the University of Utah (Salt Lake City, UT, USA), and
consisted of a 10-CGG repeat island without deletion
(WT), a single CGG deletion (SD), and a double CGG
deletion (DD).
The gel mobility shift assay was carried out using a
DIG Gel Shift Kit, 2nd Generation, purchased from Roche
Diagnostics (Indianapolis, IN, USA). Pairs of the
single-stranded synthetic oligonucleotides were annealed and
labelled with 1 mmol digoxigenin (DIG)-11-ddUTP
following the protocol outlined by the kit. Each 10 µL
binding assay contained 35 fmol DIG-labelled oligonucleotide,
300 ng rhSP1 in a 1 × binding buffer (20 mmol/L HEPES
[pH 7.6], 1 mmol ethylenediaminetetraacetic acid (EDTA),
10 mmol (NH4)2SO4, 1 mmol
dithiothreitol (DTT), 0.2% Tween-20, and 30 mmol KCl). The competition assays
contained a 10-fold molar excess of unlabelled
double-stranded oligonucleotide competitor. The binding
reactions were incubated at 23ºC for 20 min. The samples
were loaded on a 7.5% non-denaturing polyacrylamide
gel, pre-run in 0.5 × Tris-borate EDTA (TBE) buffer, pH 8.0
using a PhastSystem apparatus (GE HealthCare, Piscataway, NJ, USA). The protein-bound probe and
free probe were transferred to a positively-charged
nylon membrane (Roche Diagnostics, Indianapolis, IN,
USA) for 30 min by contact blotting as described in the
kit protocol. The membrane was washed in buffer
containing 0.1 mol/L maleic acid, 0.15 mol/L NaCl (pH 7.5),
and 0.3% Tween-20, then transferred to blocking
solution and incubated for 30 min. The membrane was then
incubated with the primary antibody solution,
anti-digoxigenin-alkaline phosphatase conjugate 1:10 000
dilution in blocking solution, for an additional 30 min. The
antibody solution was removed and the membrane was
washed twice for 15 min in washing buffer. The
membrane was labelled with the secondary conjugate, washed
twice and exposed to X-ray film. The blocking solution,
anti-digoxigenin-alkaline phosphatase conjugate, disodium
3-(4-methoxyspiro{1,2-dioxetane-3,2'-(5'-chloro) tricyclo
[3.3.1.13.7 ]decan}-4-yl)phenyl phosphate and all
reagents for labelling of oligonucleotides were supplied
with the kit. All reactions were carried out at room
temperature unless otherwise stated.
The gel shift was digitized and analyzed for shift
distance and band intensity using NIH Image J (version
1.38; National Institute of Health, Bethesda, MD, USA).
3 Results
A list of identified novel SNPs (all heterozygous) is
summarized in Table 2. Briefly, we identified three novel
SNPs in the fertile group and seven novel SNPs in the
infertile group. Of these, two SNPs were present in
both fertile and infertile groups, making for one novel
SNP unique to the fertile population, and five novel SNPs
unique to the infertile population. We also identified a
known SNP in the 5'-UTR of infertile men at a frequency
of 5.2% (tttgtcT/Gattact, rs17167484). This is
considerably lower than the previously reported frequency of
20% [4]. There was one novel exonic SNP identified in
exon 4 in 5% of infertile men consisting of a G/A
conversion (aaactaG/Ataatag, freq. 5%) that resulted in an
isoleucine for valine substitution (both non-polar, neutral
a.a.) at position 56 of the 152 a.a. UBE2B protein.
In silico protein modeling of the original and altered UBE2B
proteins revealed no differences in protein tertiary
structures.
The 5'-UTR was notable for a 10-CGG variable length
repeat sequence located at position 133735064_133735093
on chromosome 5, within the identified promoter area
approximately 100 bp upstream of the coding region
(Figure 1). A single CGG deletion (SD) was noted in both
infertile and fertile men with a frequency of 20%.
A dual CGG deletion (DD) was noted only in infertile men with a
frequency of 4.8%. Such dual CGG deletions have not
been reported previously.
DNA_protein gel shift analysis of the WT, SD, and
DD sequences found that both SD and DD sequences have twice the binding affinity to transcription factor SP1
compared to the WT sequence (Figure 2). The relative
shift of these DNA_protein complexes were similar.
Addition of unlabelled oligonucleotide in excess of labelled
oligonucleotide showed competitive binding to SP1 and
subsequent loss of signal. The negative control using
bovine serum albumin (BSA) noted no binding to WT, SD,
or DD oligonucleotides, and ruled out non-specific
DNA_protein binding. The exact molecular size of these
DNA_protein complexes was not determined as denaturation
of the SP1 protein required for size evaluation would
have disrupted native secondary and tertiary structures,
and was not critical to the evaluation of binding affinity
or relative shift.
4 Discussion
The underlying etiologies of abnormal sperm
parameters remain largely unknown [12_14]. Although
characterization of genes that cause male factor infertility have
helped clarify the genetic component of some cases of
male infertility [15_17], the majority of men with
oligospermia or non-obstructive azoospermia are normal
on karyotype evaluation and free from known endocrine
pathologies or pathophysiologic abnormalities,
highlighting the idiopathic nature of the diagnosis [18].
Of the 147 known sequence mutations within the
UBE2B gene, four are SNPs located within the 5'-UTR,
one is within the start codon of exon 1, and the
remainder are within the intronic regions of the
UBE2B gene [4]. None of these have been associated with human
male infertility.
The identification of one novel intronic SNP unique
to fertile males, and five novel intronic SNPs unique to
infertile males, is of interest. However, given the limited
numbers available to this study, designation of these SNPs
as associated with male fertility or infertility is problematic,
and would require further evaluation with larger study
populations. Assessment of our novel exon 4 SNP
revealed no significant differences in tertiary protein
structures compared to WT, and it is unlikely to alter the UBE2B
protein or be a factor in male infertility.
Variations in the CGG repeat sequence have been
previously reported in 41 unrelated individuals of
non-identified gender or ethnicity [19]. Reported were: a
sextuplet deletion (2%); single deletion (15%); no deletion
(78%); and a CGG insertion (5%). The frequency of
the single CGG deletion sequence was comparable to
our study, however the fertility status of these 41
individuals was not reported.
As the frequency of the single CGG deletion was
similar in both fertile and infertile men, at approximately
20%, the possibility exists that such findings might not
be related to male infertility. However, the determination
of increased binding affinity to SP1 of both single and
double CGG deletions suggests that such deletions are
not biologically insignificant. SP1 is a ubiquitous
transcription factor present during multiple steps of human
male spermatogenesis [11] and has been shown to act as
both a promoter and repressor of transcription [20_22].
Thus, altered binding affinity of SP1 to these single and
double CGG deletion sequences provides an enticing
theory of disease cause and mechanism with regard to
such deletions and subsequent male infertility.
Nevertheless, it is clear that such deletions alone are
not the sole or definitive cause of human male infertility.
Such deletions might represent one of several risk
factors for acquisition of male infertility. In fact, notation
of multiple SNPs as a predictor of disease has been shown
in a number of disease states such as multiple sclerosis
[23] and type 2 diabetes [24], and also have correlated
with disease severity as seen with stroke risk in sickle
cell patients [25]. Similarly, the presence of an as-yet
undefined SNP (external to the UBE2B gene) might be
required for these CGG deletions to affect male fertility.
The identification of such SNPs would require
multi-gene analysis and is best approached with current
gene-chip technology.
The significance of this study should be interpreted
within the context of the study population, that is, these
findings might only be applicable to males of northern
European ancestry. Furthermore, in addition to more
extensive SNP evaluation, additional study is indicated to
confirm altered UBE2B mRNA and protein expression
concomitant with 5'-UTR CGG deletions in populations
of men with severe oligospermia or non-obstructive
azoospermia.
Although defects in exons 1_6 of the
UBE2B gene have not been linked to human oligospermia nor
non-obstructive azoospermia, CGG deletions noted in the
5'-UTR region could affect normal transcription and
expression of the UBE2B gene product through altered
binding of transcription factor SP1 and an as-yet unidentified
co-factor. This in turn might lead to abnormal
spermatogenesis and subsequent male infertility. Further
investigations are needed to clarify whether such CGG
deletions do ultimately affect UBE2B expression through
appropriate translation studies.
References
1 Roest HP, van Klaveren J, de Wit J, van Gurp CG, Koken
MH, Vermey M, et al. Inactivation of the
HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility
associated with chromatin modification. Cell 1996; 86:
799_810.
2 Baarends WM, Wassenaar E, Hoogerbrugge JW, van Cappellen
G, Roest HP, Vreeburg J, et al. Loss of
HR6B ubiquitin-conjugating activity results in damaged synaptonemal complex
structure and increased crossing-over frequency during the male
meiotic prophase. Mol Cell Biol 2003; 23: 1151_62.
3 Roest HP, Baarends WM, de Wit J, van Klaveren JW,
Wassenaar E, Hoogerbrugge JW, et al. The
ubiquitin-conjugating DNA repair enzyme HR6A is a maternal factor essential
for early embryonic development in mice. Mol Cell Biol 2004;
24: 5485_95.
4 National Center for Biotechnology Information. Single
Nucleotide Polymorphism database available at URL:
http://www.ncbi.nlm.nih.gov/SNP/
5 Reese MG. Neural Network Promoter Prediction server
available at URL: http://www.fruitfly.org/seq_tools/promoter.html
6 Reese MG. Application of a time-delay neural network to
promoter annotation in the Drosophila
melanogaster genome. Comput Chem 2001; 26: 51_6.
7 Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL
workspace: a web-based environment for protein structure
homology modelling. Bioinformatics 2006; 22: 195_201.
8 Zemla A. LGA: a method for finding 3D similarities in protein
structures. Nucleic Acids Res 2003; 31: 3370_4.
9 Kel A. Match and TRANSFAC 6.0. Available at URL:
http://www.gene-regulation.com
10 Assumpcao JG, Ferraz LF, Benedetti CE, Maciel-Guerra AT,
Guerra G Jr, Marques-de-Faria AP, et al. A naturally occurring
deletion in the SRY promoter region affecting the Sp1 binding
site is associated with sex reversal. J Endocrinol Invest 2005;
28: 651_6.
11 Thomas K, Wu J, Sung DY, Thompson W, Powell M,
McCarrey J, et al. SP1 transcription factors in male germ cell
development and differentiation. Mol Cell Endocrinol 2007;
270: 1_7.
12 Ferlin A, Raicu F, Gatta V, Zuccarello D, Palka G, Foresta C.
Male infertility: role of genetic background. Reprod Biomed
Online 2007; 14: 734_45.
13 Sadeghi-Nejad H, Farrokhi F. Genetics of azoospermia:
current knowledge, clinical implications, and future directions.
Part I. Urol J 2006; 3: 193_203.
14 Krausz C, Giachini C. Genetic risk factors in male infertility.
Arch Androl 2007; 53: 125_33.
15 Zhang J, Qiu SD, Li SB, Zhou DX, Tian H, Huo YW,
et al. Novel mutations in ubiquitin-specific protease 26 gene might
cause spermatogenesis impairment and male infertility. Asian
J Androl 2007; 9: 809_14.
16 Tsujimura A, Fujita K, Komori K, Tanjapatkul P, Miyagawa
Y, Takada S, et al. Associations of homologous RNA-binding
motif gene on the X chromosome (RBMX) and its like
sequence on chromosome 9 (RBMXL9) with non-obstructive
azoospermia. Asian J Androl 2006; 8: 213_8.
17 Gu AH, Liang J, Lu NX, Wu B, Xia YK, Lu CC,
et al. Association of XRCC1 gene polymorphisms with idiopathic
azoospermia in a Chinese population. Asian J Androl 2007; 9: 781_6.
18 Brugh VM 3rd, Matschke HM, Lipshultz LI. Male factor
infertility. Endocrinol Metab Clin North Am 2003; 32:
689_707.
19 Lench NJ, Thompson J, Markham AF, Robinson PA. (CGG)
trinucleotide repeat polymorphism in the 5' region of the
HHR6B gene: the human homolog of the yeast DNA repair
gene RAD6. Hum Genet 1995; 96: 369_70.
20 Li R, Hodny Z, Luciakova K, Barath P, Nelson BD. Sp1
activates and inhibits transcription from separate elements in
the proximal promoter of the human adenine nucleotide
translocase 2 (ANT2) gene. J Biol Chem 1996; 271: 18925_30.
21 Zaid A, Hodny Z, Li R, Nelson BD. Sp1 acts as a repressor of
the human adenine nucleotide translocase-2
(ANT2) promoter. Eur J Biochem 2001; 268: 5497_503.
22 Zaid A, Li R, Luciakova K, Barath P, Nery S, Nelson BD. On
the role of the general transcription factor Sp1 in the activation
and repression of diverse mammalian oxidative
phosphorylation genes. J Bioenerg Biomembr 1999; 31: 129_35.
23 International Multiple Sclerosis Genetics Consortium, Hafler
DA, Compston A, Sawcer S, Lander ES, Daly MJ, Jager PL,
et al. Risk alleles for multiple sclerosis identified by a genomewide
study. N Engl J Med 2007; 357: 851_62.
24 Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren
WL, et al. A genome-wide association study of type 2 diabetes
in Finns detects multiple susceptibility variants. Science 2007;
316: 1341_5.
25 Hoppe C, Klitz W, D'Harlingue K, Cheng S, Grow M, Steiner
L, et al. Confirmation of an association between the
TNF(-308) promoter polymorphism and stroke risk in children with
sickle cell anemia. Stroke 2007; 38: 2241_6.
|